Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study Evaluating Maraviroc (Celsentri)Intensification Benefit in HIV Infected Patients Presenting Insufficient Immune Restoration Despite Controlled Viral Load With Antiretroviral Treatment. ANRS 145 MARIMUNO

Next Previous
Trial Profile

Pilot Study Evaluating Maraviroc (Celsentri)Intensification Benefit in HIV Infected Patients Presenting Insufficient Immune Restoration Despite Controlled Viral Load With Antiretroviral Treatment. ANRS 145 MARIMUNO

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maraviroc (Primary)
  • Indications HIV-1 infections
  • Focus Biomarker; Therapeutic Use
  • Acronyms MARIMUNO

Most Recent Events

  • 25 Feb 2016 Results (n=22) presented at the 23rd Conference on Retroviruses and Opportunistic Infections
  • 10 Feb 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
  • 10 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top